Key result
BMPR2 A-isoform expression shows potential as a novel prognostic biomarker for PH-LHD.
Why the study?
Targeted therapies for pulmonary hypertension associated with left heart disease are lacking, partially because the underlying molecular mechanisms remain poorly understood.
BMPR2 A-isoform expression is identified as a potential novel prognostic biomarker and therapeutic target for pulmonary hypertension secondary to left heart disease.
May inform PH-LHD risk stratification; leaves open clinical utility pending prospective validation.
Extract Pulmonary hypertension (PH) associated with left heart disease (PH-LHD) represents a major health issue worldwide, accounting for nearly 75% of cases of PH. PH-LHD eventually develops in more than half of patients with heart failure and confers poor prognosis. It is recognised that targeted therapies are lacking partially because the underlying molecular mechanisms remain poorly understood [1, 2]. Shareable abstract BMPR2 A-isoform expression is involved in PH with left heart disease and has potential as a novel prognosis biomarker, supporting the development of new therapeutic approaches targeting the BMPR2–activin type IIA receptor pathway https://bit.ly/45tywJI
No takes yet. Share an insight, caveat, or question.
Martínez-Solano et al. (2025) studied Pulmonary hypertension associated with left heart disease (PH-LHD). BMPR2 A-isoform expression is involved in pulmonary hypertension with left heart disease and has potential as a novel prognosis biomarker.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: